<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03038646</url>
  </required_header>
  <id_info>
    <org_study_id>MIN-101C06</org_study_id>
    <nct_id>NCT03038646</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open-Label, Randomised, 3-Treatment, 3-Period, Single-Dose, Crossover Study in Healthy Subjects to Compare the Pharmacokinetic Properties of Modified Release (MR) Formulations of MIN-101 Followed by Food Effect Testing of a Selected Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minerva Neurosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minerva Neurosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the pharmacokinetic (PK) profiles of MIN-l0l following administration of
           modified release (MR) formulations of MIN-l0l in healthy male and female subjects

        -  To select 1 MR formulation for use in fed state

        -  To evaluate the effect of food on the bioavailability of MIN-l0l selected MR formulation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Actual">April 20, 2017</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Plasma PK parameter, Cmax</measure>
    <time_frame>from predose up to 72 hours post dose: Blood samples for MIN-101 will be collected at time 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 48, 60, and 72 hours post-dose on Day 1 of all periods.</time_frame>
    <description>To estimate the relative bioavailability of MIN-l0l following MIN-101 administration. Plasma samples will be analyzed for MIN-101 and its metabolites using a validated LC-MS/MS method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Plasma PK parameter, Tmax</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Plasma PK parameter, Tlag</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Plasma PK parameter,partial AUC (e.g., AUC12, AUC24), AUClast, AUC∞</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Plasma PK parameter, λz and t1/2</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Plasma PK parameter, Cmax</measure>
    <time_frame>from predose up to 72 hours post dose: Blood samples for MIN-101 will be collected at time 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 48, 60, and 72 hours post-dose on Day 1 of all periods.</time_frame>
    <description>To estimate the relative bioavailability of MIN-101 and its main metabolites following the administration of the selected modified release formulation in different food conditions (fasted or fed state).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Plasma PK parameter, Tmax</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Plasma PK parameter, Tlag</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Plasma PK parameter, λz and t1/2</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: QTcF changes from baseline</measure>
    <time_frame>from predose up to 72 hours post dose</time_frame>
    <description>The effect of coincidentally measured (time-matched) plasma concentrations of MIN-l0l on QTcF changes from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Safety (AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments)</measure>
    <time_frame>2 months 16 days</time_frame>
    <description>Safety will be assessed through AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Safety (AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments)</measure>
    <time_frame>2 months 16 days</time_frame>
    <description>Safety will be assessed through AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 mg MIN-101 of the current modified-release formulation (comparator) identified as MR-32 formulation administered in the fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 mg MIN-101 MR administered in the fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 mg MIN-101 MR administered in the fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 selected dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 mg MIN-101 of MR administered in the fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIN-101</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Part 2 selected dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed CYP 2D6 extensive metaboliser genotype

          2. Subject has given voluntary written informed consent before performance of any study
             related procedure

          3. Must be 18 to 45 years of age, inclusive

          4. Subject must be a healthy male or female as indicated by the protocol

          5. Agree to abstain from all medication (except for allowed birth control for 21 days
             before the first dose with MIN-101

          6. Subject agrees to use the methods of birth control as outlined in the protocol

          7. Must be willing and able to communicate and participate in the whole study.

          8. Willing to eat all the food supplied throughout the study.

        Exclusion Criteria:

          1. A history of clinically significant gastrointestinal disease, renal, hepatic,
             neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic or psychiatric
             disease or any other condition which, in the opinion of the principle investigator,
             would jeopardize the safety of the subject or impact the validity of the study results

          2. Acute diarrhoea or constipation in the 7 days before the predicted first study day.

          3. Subject has donated blood within 90 days or plasma within 30 days of study dosing

          4. Regular alcohol consumption in males&gt; 21 units per week and Females &gt; 14 units per
             week (1 Unit = 1/2 pint beer, 25 mL of 40or a 125 mL glass of wine)

          5. Subject has a borderline or long QTc Fridericia interval as defined by screening
             readings of &gt;430 msec for males and &gt;440 for females or a personal or familial history
             of long QT syndrome

          6. Subject has participated in a clinical trial within 90 days prior to study initiation

          7. Females who are pregnant or breast feeding

          8. Subject has used any prescription medication or over-the-counter (OTC) medication,
             including vitamin supplements, within 21 days prior to day l

          9. Subject has been treated with any known P450 206 or 3A4 enzymes altering drugs within
             30 days prior to the study

         10. Subject has smoked or used nicotine products within 2 months prior to or during the
             study

         11. Subject has sought advice from or been referred to a GP or counsellor for abuse or
             misuse of alcohol, non-medical drugs, medicinal drugs or other substance abuse, e.g.
             solvents

         12. Subject has a positive blood screen for HIV, Hepatitis B surface antigen (HBsAg), and
             Hepatitis C Antibody

         13. Any current or previous use of drugs such as opiates, cocaine, ecstasy, or intravenous
             amphetamines and/or a positive urine screen for alcohol or drugs of abuse. Subjects
             who admit to occasional past use of cannabis will not be excluded as long as they have
             a negative drugs-of-abuse test and have been abstinent from cannabis use for at least
             3 months

         14. Subject has a current uncontrolled inter-current illness (i.e., active infection) or
             has had a clinically significant illness within the last 30 days prior to Day 1

         15. Subject has had major surgery within 28 days of study entry, or 12 months prior to
             study for gastrointestinal surgery.

         16. Failure to satisfy the investigator of fitness to participate for any other reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Jabbari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioKinetic Europe Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biokinetic Europe</name>
      <address>
        <city>Belfast</city>
        <zip>BT2 7BA</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2017</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Food Effect</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

